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Abstract

The protozoan parasite Trypanosoma cruzi is the etiological agent of Chagas
disease, a problem endemic to Central and South America. In recent years, this
neglected infectious disease has become a global health concern. The only clinically
available drugs for the chemotherapy of Chagas disease have important disadvantages
such as, high toxicity, strain resistance and variable efficacy. Therefore, there is an
urgent need for the development of new antichagasic agents. The enzyme Nmyristoyltransferase (NMT) has been characterized in a range of eukaryotes, from
Saccharomyces cerevisae to Homo sapiens. Moreover, NMT has been shown to be
essential in protozoan parasites, including Leishmania major and Trypanosoma brucei.
Here, we report the validation of T. cruzi NMT as a target and the discovery of lead
compounds that specifically inhibit this enzyme. The results from the first part of this
dissertation indicate that in T. cruzi NMT is constitutively expressed in all stages of the
parasite and show at least partial endoplasmic reticulum association. Moreover, we
have standardized the heterologous expression and purification of TcNMT for future
enzyme kinetics analysis and in vitro inhibition studies. In addition, we report for the first
time in trypanosomes, an alternative and rapid, non-radioactive method to study protein
myristoylation. The second part of this work focuses on the evaluation of NMT inhibitors
as anti-T. cruzi agents. These compounds were originally designed to target T. brucei
NMT; here we show their effects on the intracellular parasite T. cruzi. Compounds
DDD86481, DDD100097 and DDD100144 showed anti-proliferative characteristics in
submicromolar concentrations. Moreover, metabolic labeling with myristic acid azide
vii

showed a decreased in the myristoylation of proteins in treated parasite, providing
evidence of the “on target” activity of the inhibitors. These inhibitors hold great potential
for further exploration as urgently needed new therapeutic agents for Chagas disease.

viii

Table of Contents

Acknowledgements .......................................................................................................... v
Abstract ...........................................................................................................................vii
Table of Contents ............................................................................................................ ix
List of Tables ................................................................................................................... xi
List of Figures..................................................................................................................xii
Chapter 1: General Introduction ....................................................................................... 1
1.1 Trypanosoma cruzi and Chagas disease............................................................ 1
1.2 N-myristoyltransferase ........................................................................................ 5
1.3 Significance and aims ......................................................................................... 9
Chapter 2: Expression and Localization of N-myristoyltransferase in Trypanosoma cruzi
....................................................................................................................................... 11
2.1 Introduction ....................................................................................................... 11
2.2 Methods ............................................................................................................ 13
2.3 Results .............................................................................................................. 17
Chapter 3: Evaluation of N-myristoyltransferase Inhibitors as Anti-T. cruzi agents ....... 30
3.1 Introduction ....................................................................................................... 30
3.2 Methods ............................................................................................................ 31
3.3 Results .............................................................................................................. 38
Chapter 4: Discussion and Final Conclusions................................................................ 64
ix

4.1 Acknowledgements ........................................................................................... 68
References ..................................................................................................................... 69
Appendix ........................................................................................................................ 75
List of abbreviations ................................................................................................ 75
List of publications .................................................................................................. 77
Curriculum vitae ...................................................................................................... 78

x

List of Tables

Table 1.1. Classification of kinetoplastid N-myristoylated proteins from high confidence
groups…………………………………………………………………………………………….8
Table 3.1. IC50 values of DDD86481, DDD100097 and DDD100144……………………43

xi

List of Figures

Figure 1.1. Trypanosoma cruzi life cycle ......................................................................... 4
Figure 1.2. N-myristoylation reaction mechanism ........................................................... 7
Figure 2.1. TcNMT is constitutively expressed in all T. cruzi stages and it is associated
to the endoplasmic reticulum ......................................................................................... 19
Figure 2.2. Anti-LmNMT and anti-TbNMT recognize TcNMT........................................ 20
Figure 2.3. Anti-TcNMT shows no cross-reactivity with human cells ............................ 21
Figure 2.4. Alignment of T. cruzi NMT with NMTs from T. brucei, L. major and
Human NMTs ................................................................................................................. 22
Figure 2.5. Click Azide/Alkyne Reaction ....................................................................... 24
Figure 2.6. Myristoylated proteins are associated to the endomembrane system ........ 25
Figure 2.7. Heterologous expression of TcNMT in E. coli ............................................. 28
Figure 2.8. Purification of recombinant TcNMT ............................................................. 29
Figure 3.1. High-content imaging and data analysis ..................................................... 40
Figure 3.2. DDD compounds inhibit intracellular proliferation of T. cruzi ...................... 41
Figure 3.3. DDD compounds are trypanocidal against purified intracellular
amastigotes .................................................................................................................... 46
Figure 3.4. DDD compounds are only toxic at high concentrations against mammalian
cells ................................................................................................................................ 47
xii

Figure 3.5. DDD compounds are less effective on the epimastigote form of the
parasite .......................................................................................................................... 48
Figure 3.6. DDD compounds specifically inhibit TcNMT ............................................... 51
Figure 3.7. DDD compounds do not affect protein translation ...................................... 52
Figure 3.8. Overall levels of myristic acid in epimastigotes treated with DDD
compounds.................................................................................................................... 54
Figure 3.9. Overall levels of myristic acid in amastigotes treated with DDD
compounds..................................................................................................................... 55
Figure 3.10. Overall levels of myristic acid in trypomastigotes treated with DDD
compounds..................................................................................................................... 56
Figure 3.11. Quantitative analysis of overall levels of myristic acid in epimastigotes
treated with DDD compounds ........................................................................................ 57
Figure 3.12. TcNMT expression in epimastigotes treated with DDD compounds ......... 60
Figure 3.13. TcNMT expression in amastigotes treated with DDD compounds ............ 61
Figure 3.14. TcNMT expression in trypomastigotes treated with DDD compounds ...... 62
Figure 3.15. TcNMT is overexpressed in epimastigotes treated with DDD
compounds..................................................................................................................... 63

xiii

Chapter 1: General Introduction

1.1 Trypanosoma cruzi and Chagas disease

The flagellate protozoan Trypanosoma cruzi is the etiological agent of Chagas
disease (or American trypanosomiasis), a problem endemic to Central and South
America. Currently, there are 8-11 million infected individuals, resulting in over 15,000
deaths annually. In recent years, Chagas disease has become an emergent concern in
the USA due to the immigration from endemic areas, with an estimated 300,000
infected people (Wilkinson and Kelly 2009). Humans and a wide range of other
mammals are usually infected when the triatomine vector takes a blood meal defecating
at the same time. The metacyclic trypomastigote form of the parasite contained in the
fecal material is inoculated through the bite wound or mucous membranes (Bern,
Montgomery et al. 2008). The parasite next invades host cells where it transforms into
intracellular amastigotes. In this stage they proliferate by binary fission and eventually
differentiate into trypomastigotes. The host cell finally ruptures releasing the
trypomastigotes into the circulation where they can invade other cells or be ingested in
a blood meal by the insect vector. Alternatively, amastigotes that are prematurely
released from ruptured cells or derived from extracellular differentiation, can also invade
surrounding cells and tissues (McCabe, Remington et al. 1984). In the midgut of the
vector the trypomastigote transforms into the replicative form epimastigote. As it travels
to the hindgut it differentiates again into metacyclic trypomastigote, and the cycle is
completed when the triatomine bug takes a blood meal infecting another mammalian
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host (Figure 1.1) (Tanowitz, Kirchhoff et al. 1992). While natural transmission is the
most common, it can also be transmitted by blood transfusion and organ transplantation
or congenital infection (Epting, Coates et al. 2010). Chagas disease has three stages:
acute, indeterminate and chronic. The acute phase is characterized by circulating
parasites in the blood and lasts up to 90 days. This phase is generally asymptomatic,
although in some cases clinical signs such as, fever, skin lesions, conjunctivitis and
enlarged lymph nodes may arise. In a small population, fatal myocarditis or
meningoencephalitis can occur, with up to 5% of diagnosed cases resulting in death
(Bern, Montgomery et al. 2008; Wilkinson and Kelly 2009). In the indeterminate stage
patients are asymptomatic and parasite numbers fall under detectable levels. However,
patients are still a reservoir for the parasite, remaining capable of transmitting the
disease. Most individuals remain asymptomatic for the rest of their lives; however, about
30% of the patients will progress into the chronic stage of the disease. Manifestations of
this stage usually appear 10-20 years after the initial infection, most commonly
cardiomyopathy. Less common are the gastrointestinal pathologies of the disease, such
as, megacolon and megaesophagous (Bern, Montgomery et al. 2008; Wilkinson and
Kelly 2009). The current treatment for T. cruzi consists of two nitroheterocyclic
derivatives, benzinidazol and nifurtimox (Murta, Gazzinelli et al. 1998). These drugs
were developed empirically in the 1960s and 1970s and are very effective in the acute
stage of the disease, but have limited activity in the chronic stage of the disease (Croft,
Barrett et al. 2005). Moreover, these compounds have severe side effects and the
development of invasive lymphomas after treatment with these drugs in rabbits has
been reported (Tanowitz, Kirchhoff et al. 1992). In addition, the course of treatment lasts
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from 1-4 months, resulting in many cases in incomplete drug schedules, which leads to
the development of resistance (Wilkinson and Kelly 2009). These facts clearly point out
the urgent need for new drugs to treat Chagas disease.
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Figure 1.1. Trypanosoma cruzi life cycle.
The bite wound is inoculated with metacyclic trypomastigotes contained in the feces of
the triatomine insect (A). Highly motile metacyclic trypomastigotes rapidly invade
damaged skin, tissue or mucosa (B). Inside the host cell, the parasite is found in a
pasitophorous vacuole (C). Upon parasitophorous vacule rupture, free trypomastigotes
undergo a dramatic morphological change into the replicative amastigote form of the
parasite (D). The amastigotes continue to divide until they transform back into
trypomastigotes (E). Trypomastigotes finally rupture the cell and can be ingested by
another triatomine insect in a blood meal or they can infect surrounding cells and
tissues (G). Alternatively, extracellular amastigotes released from ruptured cells can
also infect neighboring cells or tissues (F). Modified from Lima, Oliveira et al. 2010.
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1.2 N-Myristoyltransferase

Myristoyl-CoA:protein N-Myristoyltransferase (NMT) catalyzes the attachment of
the fatty acid, myristic acid (C14:0) to the amino-terminal glycine residue of many
eukaryotic proteins (Maurer-Stroh, Eisenhaber et al. 2002). The NMT enzyme has an
ordered Bi-Bi reaction mechanism where NMT binds first to myristoyl-CoA, which
results in a conformational change that allows the peptide to bind next. The myristoylCoA:NMT-peptide complex leads to catalysis, and the Co-A product is released first
followed by the myristoylated product (Rudnick, McWherter et al. 1991) (Figure 1.2). Nmyristoylation was first described as a co-translational modification that occurs in the
nascent peptide following the removal of the initiator methionine (Wilcox, Hu et al.
1987). Later, it was established that this modification also occurs post-translationally
upon exposure of an internal glycine following caspase cleavage in apoptotic cells (Zha,
Weiler et al. 2000). This ubiquitous modification is necessary for the localization and
function of several proteins. Moreover, it increases the lipophilicity of proteins;
facilitating their association with membranes and promoting protein-protein interactions
(Farazi, Waksman et al. 2001). Myristoylation of several proteins involved in cellular
regulation and signal transduction; such as, the α subunit of several G proteins and
cAMP dependent protein kinases; has been shown crucial for their function (Mumby,
Heukeroth et al. 1990; Gaffarogullari, Masterson et al. 2011) It has been validated as an
essential protein in Saccharomyces cerevisiae (Duronio, Towler et al. 1989), Candida
albicans and Cryptococcus neoformans (Lodge, Johnson et al. 1994). Consequently,
NMT has been explored as an antifungal chemotherapeutic target (Masubuchi, Ebiike et
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al. 2003). Moreover, previous studies have identified NMT as an appropriate
chemotherapeutic target against protozoan parasites including Leishmania donovani,
Leishmania major, Trypanosoma brucei and Plasmodium falciparum (Bowyer,
Gunaratne et al. 2007; Brannigan, Smith et al. 2010; Price, Guther et al. 2010). In T.
cruzi few N-myristoylated proteins have been experimentally validated, such as, the
phosphoinositide-specific phospholipase C and the flagellar calcium-binding protein
(Wingard, Ladner et al. 2008; de Paulo Martins, Okura et al. 2010). Nevertheless,
bioinformatics analyses have predicted more than 100 proteins to be N-myristoylated
(Mills, Price et al. 2007) (Table 1.2.1). In addition, prior myristoylation is necessary
before palmitoylation of proteins, another important post-translational modification.
Palmitoylation, which is the linkage of palmitic acid (C16:0) to cysteine residues, has
been shown to be necessary for sorting to the flagellar membrane in kinetoplastids
(Emmer, Souther et al. 2009; de Paulo Martins, Okura et al. 2010). Taking all these
facts into consideration, it is expected that NMT inhibition would have pleiotropic effects
in the physiology of the parasite. Although this enzyme has been extensively
characterized in other kinetoplastids (Price, Menon et al. 2003; Panethymitaki, Bowyer
et al. 2006; Brannigan, Smith et al. 2010; Price, Guther et al. 2010), very little is known
about T. cruzi NMT.
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Figure 1.2. N-myristoylation reaction mechanism.
Myristoyl-CoA binds first to the enzyme to form the NMT:myristoyl-CoA complex,
inducing a conformational change that allows binding of the peptide. Nucleophilic
substitution proceeds via attack by the N-terminal glycine amine in the peptide on the
myristoyl-CoA thioester. CoA is released first, followed by the myristoylpeptide. Modified
from Wright, Heal et al. 2010.
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Table 1.1. Classification of kinetoplastid N-myristoylated proteins from high confidence
groups. Modified from Mills, Price et al. 2007.
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1.3 Significance and Aims

Historically, Trypanosoma cruzi transmission was concentrated in rural areas in
Latin America, where the poor housing conditions allowed constant contact with the
triatomine insect vector. However, in the last decades large-scale migration from rural
areas has brought infected individuals to large cities both within and outside Latin
America. In the US, several species of the triatomine bug have been found in the
southwest of the country. Moreover, there are as many as 300,000 people living the US
with Chagas disease (Bern, Kjos et al. 2011). The mild and non-specific symptoms that
most patients experience, often results in misdiagnosis.
Alarmingly, only two drugs with proven efficacy are available to treat Chagas
disease. Nonetheless, neither drug is approved by the US Federal Drug and Food
Administration (FDA) and can only be obtained through the CDC and used under
investigational protocols. Both drugs are highly toxic and have limited efficacy against
established chronic-stage disease, which highlights the urgent need for new
chemotherapeutics against T. cruzi. This requires the identification of enzymes and
metabolic pathways in the parasite that could be used as potential targets for drug
development. These enzymes have to be present in the mammalian stages of the
parasite. Moreover, given that in the mammal, T. cruzi resides mainly intracellularly, the
drugs must be able to enter the host cell to reach the parasite. Validation of drug targets
and compounds that satisfy these requirements can lead to improved therapies against
Chagas disease.
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The aims of this dissertation are twofold: 1) To investigate the expression and
localization

of

N-myristoyltransferase

in

T.

cruzi,

and

2)

to

evaluate

N-

myristoyltransferase inhibitors as anti-T. cruzi agents.
Previous studies have extensively characterized NMTs from a wide range of
eukaryotes. It has been shown to be an essential enzyme in the kinetoplastids T. brucei,
L. major and L. donovani. Moreover, selective inhibition of NMT in these parasites leads
to parasite death. In mice infected with T. brucei, NMT inhibitors cures acute
trypanosomiasis. Despite the impressive advances in understanding this protein
modification, very little is known about T. cruzi NMT. Therefore, the focus of Chapter 2
is to determine if NMT is expressed in all the stages of the parasite, particularly in the
mammalian stages, and therefore be considered as a potential chemotherapeutic
target. Consequently, Chapter 3 focuses on the chemical evaluation of this enzyme as
a target using specific NMT inhibitors. Also, the effects of these inhibitors on T. cruzi
intracellular proliferation and their “on target” effect are evaluated.
Taken together, the studies described here provide a greater understanding of T.
cruzi NMT and validate this enzyme as a drug target for Chagas disease. Moreover,
they provide a promising start in the characterization of specific inhibitors that will
contribute in the critical search for more effective and less toxic drugs against this
parasite.
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Chapter 2: Expression and Localization of N-myristoyltransferase in
Trypanosoma cruzi

2.1

Introduction
Myristoylation of proteins is catalyzed by the ubiquitously distributed eukaryotic

enzyme N-myristoyltransferase. The importance of this modification in the function of
proteins involved in signaling or other fundamental cellular processes has brought
attention to this enzyme. NMT has been characterized in a range of eukaryotes,
including Saccharomyces cerevisiae (Duronio, Towler et al. 1989), Plasmodium
falciparum (Gunaratne, Sajid et al. 2000), T. brucei (Panethymitaki, Bowyer et al. 2006),
L. major (Price, Menon et al. 2003) and human cells (McIlhinney and McGlone 1996). In
Saccharomyces cerevisiae NMT has been shown to be a cytosolic protein that is not
associated with cellular membranes (Knoll, Levy et al. 1992). Conversely, NMTs from
Drosophila (Ntwasa, Egerton et al. 1997), Arabidopsis thaliana (Qi, Rajala et al. 2000)
and mammalian cells are known to be partially membrane-associated (Raju, Magnuson
et al. 1995; McIlhinney and McGlone 1996). In L. major >70% of this enzyme is
associated with membranes (Price, Menon et al. 2003), while in T. brucei it is equally
distributed between membranes and the cytosol (Panethymitaki, Bowyer et al. 2006).
Here we provide the first evidence that T. cruzi NMT (TcNMT) is expressed in all
the stages of the parasite. Additionally, we demonstrate that NMT is at least partially
associated with the endoplasmic reticulum (ER) by colocalization with BiP (binding
protein), an ER resident. Moreover, we show that many of the residues predicted to be
11

implicated in the enzyme mechanism or to have regulatory roles are conserved in
TcNMT. We also provide the first insight on the distribution of myristoylated proteins in
T. cruzi using a bioorthogonal labeling method. Furthermore, we have standardized the
heterologous expression and purification of recombinant TcNMT, which will allow for
future biochemical characterization of this enzyme and for in vitro inhibition studies
using larger libraries of compounds.
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2.2 Methods

Parasite and mammalian cell culture
LLC-MK2 (green monkey kidney epithelial cells) and U2OS (human osteocytes) (ATCC)
cells were culture in high glucose Dulbeco’s Modified Eagle Medium (DMEM)
supplemented with 10% heat inactivated-fetal bovine serum (HI-FBS) at 37°C, under
5% CO2 atmosphere. Tissue culture cell-derived trypomastigote forms of T. cruzi (TCT)
(Y strain) were obtained 5 to 9 days after infection of LLC-MK2 monolayers as
previously described (Andrews and Colli 1982). T. cruzi epimastigotes (Epis) (Y strain)
were maintained axenically in liver infusion tryptose (LIT) medium at 28°C, as previously
described (Camargo 1964).

Purification of intracellular amastigotes (ICA)
LLC-MK2 cells were infected with 108 TCTs. After 5 days, the infected monolayers were
gently detached by scraping and resuspended in 5 mLs of phosphate buffered saline
(PBS). The suspension containing the infected cells was next transferred to an M-tube
(Miltenyi, Biotec). This tube bears a special stator and rotor that allows for tissue
homogenization. Also, it has a pre-inserted mesh that retains larger particles, removing
them from the homogenized sample. The tube was then placed in the gentleMACS™
Dissociator (Miltenyi, Biotec) for the automated disruption of host cells. The
homogenized sample containing the parasites was then passed through a column
containing anion exchange preswollen microgranular diethylaminoethyl cellulose (DE52,
Whatman). The sialylated TCT forms of the parasites were retained in the resin through
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ionic interaction, while the ICA forms were recovered (Marques 2011).

Immunofluorescence Assay
Parasites were washed with phosphate buffered saline (PBS) and 104 cells per well
were deposited on a 96-well plate, followed by centrifugation at 3500 rpm for 10 min at
room temperature. Supernatant was removed and cells were fixed with 4%
paraformaldehyde (PFA) for 15 min at room temperature, then permeabilized with 0.1%
Triton X-100 in PBS for 10 min. Wells were blocked for 1 hour at room temperature with
3% bovine serum albumin (BSA) in PBS. To obtain polyclonal anti-TcNMT, rabbit sera
was rose against the TcNMT peptide RGDGNLHYYFYNWSYP (Biomatik). Anti-TcNMT
was labeled with Alexa® 594, while rabbit anti-TbBiP (gift from James Bangs, University
at Buffalo) was labeled with Alexa® 488, using the APEX Antibody Labeling Kits (Life
Technologies) according to the manufacturer instructions. Parasites were incubated
overnight with the primary antibodies, both at 1:250 dilution in 3% BSA-PBS. To remove
unbound antibody, cells were washed 3X with PBS with 0.1% Tween (0.1% PBS-T).
Parasite DNA was then labeled with 4’,6-diamidino-2-phenylindole (DAPI) at 0.5 µg/mL.
Samples were visualized using a LSM 700 Confocal Microscope (Zeiss) with a 63X oil
objective lens. Images were acquired using the ZEN 2009 software (Zeiss).

Infection of U2OS cells
Human osteocytes (U2OS cells) were diluted in 10% HI-FBS, DMEM to give a cell
density of 2 x 105 cells/mL. TCTs were resuspended in 10% HI-FBS, DMEM to a final
density of 1.2 x 107 cells/mL. Cells and parasites were mixed at a ratio of 4 volumes of
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cells plus 1 volume of parasites. For non-infected cells, U2OS cells were diluted in
DMEM, 10% HI-FBS to give a cell density of 2 x 105 cells/mL. 150 µL of the mixture
were dispensed per well. Plates were incubated for 72 or 96 hours at 37°C under 5%
CO2 atmosphere. Immunofluorescence assay was performed as described above using
anti-TcNMT at 1:250 dilution, followed by anti-rabbit IgG Alexa® 594 conjugated. Host
cell and parasite DNA was labeled using DAPI at 0.5 µg/mL. Samples were visualized
and images acquired as described above.

Metabolic labeling and fluorescence microscopy
107 parasites were washed with PBS three times and incubated at 37°C in the case of
ICA and TCT, and at 28°C in the case of Epis, in 1mL of 2% delipidated bovine serum
albumin (BSA), DMEM. After 30 min, 100 µM of myristic acid azide (Life Technologies)
was added from 50 mM stock solutions in dimethyl sulfoxide (DMSO). The same
volume of DMSO was used as a negative control. Parasites were further incubated for 6
hours. For confocal microscopy analysis, samples were processed as described above.
After permeabilization, cells were washed three times with 3% BSA in PBS. “Click”
reaction between the myristic acid azide and Alexa Fluor 488® alkyne (Invitrogen) was
performed according to the manufacturer instructions using the Click-iT® Cell Reaction
Buffer Kit (Life Technologies). Parasite DNA was labeled with DAPI at 0.5 µg/mL.
Samples were visualized and images acquired as described above.
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PCR amplification, cloning and expression
The TcNMT gene was amplified from T. cruzi Y strain genomic DNA using the primers
NMTfow (5’-GGATCCATGGCAGAAGAGGGTTCAGGT-3’) and NMTrev (5’-GAATTCCTATAGCATGAACAATCCCACGTC-3’) based on the gene sequence AI069625. The
BamHI and EcoRI sites used to clone the amplified fragment into the vector pRSETA
(Life Technologies) are underlined. The resulting plasmid pNMTtc was transformed in
Escherichia coli BL21 (DE3) for expression. Expression of N-terminally His6-tagged
recombinant protein was induced after growth at 37°C to A600 (absorbance) of 0.6 by
addition of IPTG (isopropyl β-D-thiogalactoside) to 1 mM final concentration. Expression
was confirmed by Coomassie blue staining after SDS-PAGE several time points after
induction. After another 12 hours of growth at 18°C, the bacterial cells were lysed in
buffer A (20 mM Tris, 1 M NaCl, 10mM Immidazole) and centrifuged at 18000 g for 45
min to pellet insoluble material, prior to immobilized metal ion affinity chromatography
using a HisTrap™ HP column (GE Healthcare Life Sciences). The His6-tagged protein
was eluted using fast protein liquid chromatography (FPLC) with a gradual increase of
immidazole from 10 to 500 mM using buffer B (20 mM Tris, 1 M NaCl, 500 mM
Immidazole). TcNMT was visualized by Coomassie blue staining after SDS-PAGE and
by western blotting using mouse anti-Xpress™ (Life Technologies) at 1:5000 dilution,
followed by anti-mouse IgG HRP-conjugated for detection.
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2. 3

Results

NMT Expression and Localization in T. cruzi
To investigate the expression and cellular localization of TcNMT during the T.
cruzi life cycle, epimastigotes (Epi), intracellular amastigotes (ICA) and tissue cell
culture-derived trypomastigotes (TCT) were analyzed by immunofluorescence. AntiTcNMT

was

obtained

from

rabbit

sera

rose

against

the

TcNMT

peptide

RGDGNLHYYFYNWSYP (Biomatik). Anti-TcNMT showed that NMT is excluded from
the nucleus in all three stages and a punctate appearance indicates that it is mostly
associated to the endomembrane system and other intracellular sites in the parasite. To
further determine the subcellular localization of TcNMT we use anti-TbBiP as an
endoplasmic reticulum marker (Bangs, Uyetake et al. 1993). Colocalization with BiP
suggests that NMT is at least partially associated to the endoplasmic reticulum (ER) of
T. cruzi (Figure 2.1). Together, these results demonstrate that TcNMT is constitutively
expressed in all the stages of the T. cruzi life cycle and that it is associated to the ER.
To determine the specificity of anti-TcNMT human osteocytes were infected and
analyzed by immunofluorescence. Anti-TcNMT readily labeled intracellular parasites
while non-infected cells were not labeled, indicating that there is no cross-reactivity
between this antibody and human cells (Figure 2.2). TcNMT shares 59% and 57%
overall amino acid identity with NMTs from T. brucei and Leishmania major,
respectively. Therefore, antiserum rose against LmNMT and TbNMT also recognized
TcNMT in epimastigotes (Figure 2.3) The expression and distribution of TcNMT is
consistent with that seen in Leishmania and T. brucei (Price, Menon et al. 2003;
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Panethymitaki, Bowyer et al. 2006), where NMT is also expressed in both the vector
and the mammalian forms of the parasites. Sequence analysis showed that similar to
TbNMT and LmNMT, TcNMT is divergent in its N-terminus from all NMTs so far
characterized. Interestingly, even though our data suggests ER association, TcNMT
does not contain the lysine-rich regions that have been associated with ribosomal
targeting in human and mouse NMTs (Glover, Hartman et al. 1997). In contrast, NMT
residues that have been predicted to be essential for the activity of this enzyme,
including the two negatively charged residues that have been predicted to form the floor
of the active site pocket in C. albicans NMT (Johnson, Bhatnagar et al. 1994; Weston,
Camble et al. 1998), are conserved in TcNMT. An insertion of

~ 20 amino acids is

found close the first “pocket floor” in TbNMT and LmNMT relative to human and fungal
NMTs (Price, Menon et al. 2003). In the same localization a 34 amino acid-insertion is
observed in TcNMT. An additional insertion in TbNMT and TcNMT is found further
downstream. These differences between parasite NMTs and fungal and mammalian
NMTs suggest that the enzyme activity might be affected by additional secondary or
tertiary structures formed in these parasites NMTs relative to human and fungal
enzymes (Figure 2.4).
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Figure 2.1. TcNMT is constitutively expressed in all T. cruzi stages and it is associated
to the endoplasmic reticulum.
Immunofluorescence microscopy of Epis, ICAs and TCTs. Cells are shown as viewed
under phase contrast, visualized for fluorescence with anti-TcNMT (red) and anti-BiP
(green), co-stained with DAPI to reveal positions of the nucleus and kinetoplast (blue).
Scale bar, 2 µm.
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Figure 2.2. Anti-LmNMT and anti-TbNMT recognize TcNMT.
Immunofluorescence microscopy of Epis stained with anti-LmNMT and anti-TbNMT
(red), co-stained with DAPI (blue) to reveal positions of the nucleus and kinetoplast
(blue). Scale bar, 5 µm.
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Figure 2.3. Anti-TcNMT shows no cross-reactivity with human cells.
Immunofluorescence microscopy of non-infected and infected cells 72 and 96 hours
post-infection stained with anti-TcNMT (red), co-stained with DAPI (blue) to visualize
host cell and parasite DNA. Scale bar, 10 µm.
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Figure 2.4. Alignment of T. cruzi NMT with NMTs from T. brucei, L. major and human.
The deduced open reading frame of TcNMT (AI069625) was aligned with TbNMT
(TRYP10.0.001826-6), LmNMT (AF3059561) and human NMT (HUMAN, P30419)
using the ClustaW multiple sequence alignment program (www.ebi.ac.uk/clustaw).
Strictly conserved residues are shown in red. The insertions in the parasites NMTs are
underlined. Red boxes indicate key residues involved in myristoyl-CoA binding; black
boxes indicate residues involved in peptide binding identified in yeast species. Arrows
identify the pocket floor residues in C. albicans.
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Myristic acid azide-labeled proteins are associated to the endomembrane system
It has been shown that metabolic labeling with azido-fatty acid analogs followed
by “click” reaction with an alkyne-containing fluorophore, results in fluorescently labeled
fatty-acylated proteins (Charron, Zhang et al. 2009). To visualize the distribution of Nmyristoylated proteins we first labeled Epis, ICA and TCT with myristic acid azide (Life
Technologies). This azide tag is small enough to permit the incorporation of the tagged
myristic acid molecule onto proteins by N-myristoyltransferase. In addition, previous
studies have shown that treatment with Triton X-100 solubilizes and extracts fatty acid
chemical reporters that are not installed onto proteins (Charron, Zhang et al. 2009).
Therefore

after

fixing,

we

permeabilized

with

Triton

X-100

and

performed

chemoselective ligation or “click” reaction between the azide and Alexa Fluor® 488
alkyne (Life Technologies) (Figure 2.5). By following this protocol we could ensure that
the majority of the Alexa Fluor® 488 signal corresponds mostly to putative Nmyristoylated

proteins.

The

IFA

showed

a

punctate

appearance

indicating

endomembrane association (Figure 2.6). A faded signal was detected in the control
samples where no myristic acid azide was added. The signal was mostly localized to
the nucleus and it probably represents some non-specific Alexa Fluor® 488 alkyne
accumulation. Overall, these results are consistent with the notion that N-myristoylation
targets proteins to membranes (McIlhinney 1998) .
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A

B

Figure 2.5. Click Azide/Alkyne Reaction.
In the first step myristic acid azide (A) is actively incorporated into the cells. The second
step or detection step (B) utilizes chemoselective ligation or “click” chemistry where the
azide in the myristoylated proteins reacts with an alkyne-containing dye or hapten.
Modified from MOLECULAR PROBES ®.
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Figure 2.6. Myristoylated proteins are associated to the endomembrane system.
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Fluorescence microscopy of Epis, ICAs and TCTs metabolically labeled with DMSO or
myristic acid azide were reacted with Alexa® 488 alkyne (green) after permeabilization,
co-stained with DAPI (blue) to label the nucleus and kinetoplast. Scale bar, 5 µm.
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Expression and purification of recombinant TcNMT
Establishment of robust expression and purification methods for recombinant
NMTs from L. major, T. brucei (Panethymitaki, Bowyer et al. 2006) and P. falciparum
(Bowyer, Gunaratne et al. 2007) in E. coli has allowed for well established fungal NMTs
inhibitors to be tested in vitro, using a “piggyback” approach (Gelb, Van Voorhis et al.
2003). For future biochemical characterization and in vitro inhibition studies, we
standardized the expression and purification of the recombinant T. cruzi NMT. The
TcNMT gene was cloned into pRSETA (Life Technologies) for expression of His6tagged enzyme. TcNMT was found in the insoluble fraction of E. coli when expressed at
37°C and 30°C. To obtain soluble enzyme, TcNMT was expressed at 18°C, samples
taken up to 4 hours post induction were analyzed by SDS-PAGE follow by Coomassie
blue staining. Figure 2.7 shows that NMT is mostly present in the soluble fraction.
TcNMT was purified by immobilized metal ion affinity chromatography using a
HisTrap™ HP column (GE Healthcare Life Sciences) (Figure 2.8). The activity of this
recombinant protein remains to be elucidated. However, the standardization of this
technique offers a starting point in the biochemical characterization of TcNMT.
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A

B

Figure 2.7. Heterologous expression of TcNMT in E. coli.
Insoluble (A) and soluble (B) fractions of samples obtained at different time points postinduction were analyzed by SDS-PAGE and Coomassie staining.
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A

B

Figure 2.8. Purification of recombinant TcNMT.
Different elution fractions of TcNMT during purification were visualized by SDS-PAGE
followed by Coomassie staining (A) and by western blotting (B).
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Chapter 3: Evaluation of N-myristoyltransferase Inhibitors as Anti-T. cruzi Agents

3.1 Introduction

The extensive cellular functions of N-myristoyltransferase have led to numerous
investigations of this enzyme as a target for the development of anticancer, antifungal
and antiviral compounds (Georgopapadakou 2002; Hill and Skowronski 2005;
Selvakumar, Lakshmikuttyamma et al. 2007). In protozoan parasites a “piggyback”
approach has been used, where compounds designed to target cancer and fungal
NMTs are tested for their inhibitory properties against parasites (Panethymitaki, Bowyer
et al. 2006; Bowyer, Gunaratne et al. 2007).
More recently, potent inhibitors against T. brucei NMT (TbNMT) were identified
through an initial screening of 62,000 diversity-based compound library. Optimization of
the screening hit led to TbNMT inhibitors that prevented the proliferation of bloodstream
form of T. brucei with a window of selectivity of over 200-fold with respect to mammalian
cells (Frearson, Brand et al. 2010; Brand, Cleghorn et al. 2012). Although these
compounds presented high inhibition both, in vitro and in vivo, against the extracellular
bloodstream form of T. brucei, their effects against intracellular parasites such as T.
cruzi have not been elucidated. In this study we evaluated the effect of eight of these
inhibitors against Trypanosoma cruzi. Our results not only demonstrate the potential of
the tested compounds as anti-T. cruzi agents, but also validate TcNMT as a potential
chemotherapeutic target in Chagas disease.
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3.2

Methods

Parasite and mammalian cell culture
LLC-MK2 (green monkey kidney epithelial cells) and U2OS (human osteocytes) (ATCC)
cells were culture in high glucose Dulbeco’s Modified Eagle Medium (DMEM)
supplemented with 10% heat inactivated-fetal bovine serum (HI-FBS) at 37°C, under
5% CO2 atmosphere. Tissue culture cell-derived trypomastigote forms of T. cruzi (TCT)
(Y strain) were obtained 5 to 9 days after infection of LLC-MK2 monolayers as
previously described (Andrews and Colli 1982). T. cruzi epimastigotes (Epis) (Y strain)
were maintained axenically in liver infusion tryptose (LIT) medium at 28°C, as previously
described (Camargo 1964).

Purification of intracellular amastigotes (ICA)
LLC-MK2 cells were infected with 108 TCT. After 5 days, the infected monolayers were
gently detached by scraping and resuspended in 5 mLs of phosphate buffered saline
(PBS). The suspension containing the infected cells was next transferred to an M-tube
(Miltenyi, Biotec). This tube bears a special stator and rotor that allows for tissue
homogenization. Also, it has a pre-inserted mesh that retains larger particles, removing
them from the homogenized sample. The tube was then placed in the gentleMACS™
Dissociator (Miltenyi, Biotec) for the automated disruption of host cells. The
homogenized sample containing the parasites was then passed through a column
containing anion exchange preswollen microgranular diethylaminoethyl cellulose (DE52,
Whatman). The sialylated TCT forms of the parasites were retained in the resin through
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ionic interaction, while the ICA forms were recovered (Marques 2011).

Compounds
Compounds DDD86481, DDD85646, DDD87769, DDD99837, DDD100097, DDD99742,
DDD100153 and DDD100144 were obtained from our collaborators Dr. Stephen Brand
and Dr. Paul Wyatt (University of Dundee, UK). Patent WO2010/026365.

In vitro proliferation assay
Compounds DDD86481, DDD85646, DDD87769, DDD99837, DDD100097, DDD99742,
DDD100153 and DDD100144 and the reference drug Benznidazol (BZ) were prepared
6X concentrated in 6% DMSO, to give a final concentration of 1X compound in 1%
DMSO. 30 µL of the compounds were plated to give the final concentrations of 50, 10,
1, 0.1, 0.01 and 0.001 µM, while BZ was plated at a final concentration of 800, 400 and
40 µM. DMSO control wells contained 30 µL of 6% DMSO. Human osteocytes (U2OS
cells) were diluted in Dulbeco’s Modified Eagle Medium (DMEM), 10% heat inactivatedfetal bovine serum (HI-FBS) to give a cell density of 2 x 105 cells/mL. T. cruzi
trypomastigotes were resuspended in 10% HI-FBS, DMEM to a final density of 1.2 x
107. Cells and parasites were mixed a ratio of 4 volumes of cells plus 1 volume of
parasites. 150 µL of the mixture were dispensed per well. Plates were incubated for 48
hours. After the incubation period, media was removed from the wells and 100 µL of 4%
parafolmaldehyde (PFA) were added. After 15 minutes of incubation at room
temperature, PFA was removed and cells and parasites were stained with Draq5™
(Biostatus Limited) at a concentration of 5 µM diluted in PBS. The plates were then read
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in an automated microscope.

High-content imaging
Image acquisition and analyses of the plates were carried out using the BD Pathway
855 high-resolution fluorescence bioimager system (BD Biosciences). Filter sets
appropriate for the excitation and emission spectra of Draq5 were utilized. Images from
four fields (2 x 2 montage) were acquired per well with a 20x objective. To perform the
host cell segmentation and counting of parasites, the BD AttoVision™ v1.6.2 Sub
Object analysis was used. Draq5 creates a background, staining the host cell and
parasite nucleus, but defining the cytoplasm as well, determining this way the amount of
parasites within each mammalian cell. The host cell nucleus was excluded by size
difference. Raw data was imported into the BD™ Image Data Explorer (BD
Biosciences) to determine the percentage of infected cells containing at least 1, at least
3 or at least 5 parasites.

Cytotoxicity assay
Compounds DDD86481, DDD85646, DDD87769, DDD99837, DDD100097, DDD99742,
DDD100153 and DDD100144 and the reference drug Benznidazol (BZ) were prepared
6X concentrated in 6% DMSO, to give a final concentration of 1X compound in 1%
DMSO. 30 µL of the compounds were plated to give the final concentrations of 50, 10,
1, 0.1 and 0.01 µM. DMSO control wells contained 30 µL of 6% DMSO, while wells for
the negative control contained 1% hydrogen peroxide in media. U2OS cells were diluted
in 10% HI-FBS, DMEM to give a cell density of 2x105 cells/mL, while ICA were
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resuspended to a final density of 1x107 per well. Epis were resuspended in LIT to a
density of 1x106 parasites per well. 150 µL of the suspension containing either cells or
parasites were added per well, followed by a 48 hour-incubation for U2OS cells, 24
hours for ICA, 48 and 72 hours for Epis. After 47 hours of incubation for mammalian
cells and 23 for parasites, a mixture of Propidium Iodide (Invitrogen) and Hoescht
(Invitrogen) diluted in culture media (1 µg/mL each) was added to the plates. After one
hour of incubation, plates were read in an automated microscope. In the case of the
Epis, after 44 or 68 hours of incubation 18 µL of Alamar Blue (AbD Serotec) were added
per well. After further incubation of 4 hours, the plate was read in a microplate
fluorometer (Thermo Scientific) at excitation 560nm, emission 590 nm.

Determination of IC50
IC50 were determined using GraphPad software (GraphPad Software, Inc.) using a
sigmodial dose-response variable slope model with response values based on the total
number of parasites or cells (normalized to span de range from 0 to 100%) plotted
against the logarithm of compound concentration.

In-Gel Western Blot
107 parasites were incubated with or without 10 µM of the inhibitors DDD86481,
DDD100097 and DDD100144 in 1 mL of 2% delipidated bovine serum albumin (BSA),
DMEM at 37°C for ICA and TCT and at 28°C for Epis. After 6 hours, 100 µM of myristic
acid azide (Life Technologies) (from 50 mM stock in DMSO) were added to the
samples, and the same volume of DMSO was added to the negative control. Cells were
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incubated for another 6 hours, for a 12-hour treatment with the inhibitors. Next, the
parasites were washed three times with PBS and lysed in 1% SDS, Tris HCl, pH 8.0.
“Click” reaction was performed between the myristic acid azide and Biotin Alkyne (Life
Technologies) according to the manufacturer instructions using the Click-iT® Protein
Reaction Buffer Kit (Life Technologies). Duplicate aliquots of lysates were ran in 10%
SDS-PAGE followed by fixing (5% acetic acid, 50% isoprapanol) for 15 min. Gels were
then analyzed by in-gel western blot using IRDye® streptavidin (Licor) 1:7500 in 5%
BSA, 0.05% SDS, 0.2% Tween in PBS, for 1 hour at room temperature. They were
subsequently treated or not with 0.2 M NaOH in methanol for 1 hour at room
temperature. Gels were scanned in an ODYSSEY® quantitative imagining system
(Licor). Next, they were stained with Coomassie blue and scanned again to determine
total protein levels.

[35S] Methionine labeling
107 parasites were incubated with or without 10 µM of the inhibitors as described above.
After 10 hours, cells were starved in methionine deficient media for 1 hour. Next, 20 µCi
mL-1 of [35S] methionine (Perkin Elmer) were added to the samples for 1 hour
incubation, for a 12-hour treatment with the inhibitors. Parasites were then washed
three times with PBS and lysed in 1% SDS, Tris HCl, pH 8.0. Samples were ran in 412% gels (Expedeon) and transferred to polyvinylidene fluoride (PVDF) membranes.
Membranes were dried and exposed to film. To determine total protein levels,
membranes were stained with Ponceau S after exposure.
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Metabolic labeling and fluorescence microscopy
107 parasites were incubated with or without 10 µM of the inhibitors DDD86481,
DDD100097 and DDD100144 in 1 mL of 2% delipidated BSA-DMEM at 37°C for ICA
and TCT and at 28°C for Epis. After 6 hours, 100 µM of myristic acid azide (from 50 mM
stock in DMSO) were added to the samples, and the same volume of DMSO was added
to the negative control. Parasites were further incubated for 6 hours for a total treatment
of 12 hours with the inhibitors. Cells were washed with phosphate buffered saline (PBS)
and deposited on a 96-well plate, followed by centrifugation at 3500 rpm for 10 min at
room temperature. Supernatant was removed and cells were fixed with 4%
paraformaldehyde (PFA) for 15 min at room temperature, then permeabilized with 0.1%
Triton X-100 in PBS for 10 min. After permeabilization, cells were washed three times
with 3% BSA in PBS. “Click” reaction between the myristic acid azide and Alexa Fluor
488® alkyne (Life Technologies) was performed according to the manufacturer
instructions using the Click-iT® Cell Reaction Buffer Kit (Life Technologies). Parasite
DNA was labeled with 4’,6-diamidino-2-phenylindole (DAPI) at 0.5 µg/mL. Samples
were visualized using a LSM 700 Confocal Microscope (Zeiss) with a 63X oil objective
lens. Images were acquired using the ZEN 2009 software (Zeiss).

Immunofluorescence Assay
107 parasites were incubated for 12 hours with or without 10 µM of the inhibitors
DDD86481, DDD100097 and DDD100144 in DMEM, 10% HI-FBS, DMEM at 37°C for
ICA and TCT and at 28°C for Epis. Parasites were fixed and permeabilized as
described above. Wells were then blocked for 1 hour at room temperature with 3%
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BSA-PBS. To obtain polyclonal anti-TcNMT, rabbit serum was rose against the TcNMT
peptide RGDGNLHYYFYNWSYP (Biomatik). Parasites were incubated overnight with
anti-TcNMT at 1:250 dilution in 3% BSA-PBS, followed by anti-rabbit IgG Alexa® 594
conjugated. Parasite DNA was then labeled with DAPI at 0.5 µg/mL. Samples were
visualized and images acquired as described above.

Statistical analysis
Statistical significance for the in-cell western blot data was determined by Student’s ttest using GraphPad software (GraphPad Software Inc.). Differences were considered
to be statistically significant up to p value <0.05.

Western Blot
107 parasites were incubated with or without 10 µM of the inhibitors DDD86481,
DDD100097 and DDD100144 in 1 mL of 10% HI-FBS, DMEM at 37°C for ICA and TCT
and at 28°C for Epis for 12 hours. Next, parasites were washed three times with PBS
and lysed in 1% SDS, Tris HCl, pH 8.0. Samples were run in 10% SDS-PAGE followed
by western blot probed with anti-TcNMT at dilution 1:1000 in 5% milk-PBS overnight.
This was followed by incubation with anti-rabbit IgG-HRP conjugated. The membrane
was next stripped with boiling stripping buffer (3% SDS, 0.3% β-mercaptoethanol) for 10
min, followed by 4 washes with 0.1% PBS-T. It was then blot again with anti-BiP at
dilution 1:500 in 5% milk-PBS overnight, followed by anti-rabbit IgG HRP-conjugated.
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3.3.

Results

DDD compounds inhibit T. cruzi intracellular proliferation

Previous

studies

demonstrated

the

efficacy

of

the

studied

pyrazole

sulphonamides as NMT inhibitors against T. brucei (Frearson, Brand et al. 2010; Brand,
Cleghorn et al. 2012). Based on these studies, we tested selected compounds to
determine their effects against the intracellular proliferation of T. cruzi on human
osteocytes (U2OS cells). Draq5 (Biostatus Limited) stains nucleic acids; however, it
creates a background defining the cytoplasm of the host cell. Therefore, it stains the
nucleus of the host cell and the parasite with a higher intensity, while staining the
cytoplasm of the mammalian cell with a fainter intensity, rendering the software able to
distinguish one from the other. An example of the segmentation performed on the
fluorescence bioimager is shown in Figure 3.1. Upon entering the cell, trypomastigotes
differentiate into replicative amastigote forms and begin to divide. Approximately 96
hours after infection the parasite transforms again into trypomastigotes, finally rupturing
the cell and releasing the parasites into the extracellular milieu (Epting, Coates et al.
2010). Since we are interested in the antiproliferative effects of the compounds, we
incubated for 48 hours prior to fixation. At this time point, significant replication of the
parasite is observed with little host cell disruption. To determine the percentage of
infected cells, we performed a constriction by obtaining the number of cells containing at
least one parasite (Figure 3.2.A). We did not see significant differences between the
untreated wells and the wells treated with the compounds. To determine the
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proliferation inside the mammalian cells, the number of cells containing at least 3
(Figure 3.2.B) or 5 (Figure 3.2.C) parasites was plotted. Compounds DDD86481,
DDD100097 and DDD100144 showed inhibition of intracellular proliferation, with
submicromolar IC50 of 0.175 µM, 0.258 µM and 0.346 µM respectively (Table 3.1).
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Figure 3.1. High-content imaging and data analysis.
Representative images of cells treated with the vehicle control (DMSO), untreated,
treated with 800 µM Benznidazol or 10 µM DDD100144, stained with Draq5 (left panel).
Artificial images created after segmentation on the fluorescence bioimager (right panel).
Host cells are shown in blue, extracellular parasites in red and intracellular parasites in
pink.
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A

B

C

Figure 3.2 DDD compounds inhibit intracellular proliferation of T. cruzi.
The multiparametric data obtained on a cell-by-cell basis was analyzed to determine
several parameters associated to infection of host cells by T. cruzi including the (A)
percentage of cells infected with at least one parasite (percentage of infected cells),
percentage of cells infected with (B) at least 3 or (C) at least 5 parasites (percentage of
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cells in which the parasite proliferated).
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Table 3.1. IC50 values of DDD86481, DDD100097 and DDD100144.
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DDD compounds are trypanocidal and not toxic to mammalian cells

These compounds were originally synthesized to target an extracellular parasite,
namely T. brucei. Therefore, we wanted to determine if the cytotoxic effects against the
intracellular parasite T. cruzi could be increased once the barrier of host cell membrane
was not present. It is possible that a delivery method that will help the translocation of
these compounds from the extracellular milieu into the host cell would increase the
potency of the inhibitors against the parasite. To determine the effects directly on
intracellular amastigotes (ICA), we purified them from the host cells and incubated them
with the inhibitors for 24 hours. As expected, compounds DDD86481, DDD100097 and
DDD100144 which were the most effective at inhibiting proliferation were also the most
cytotoxic displaying an IC50 of 1.83 µM, 0.059 µM and 0.017 µM, respectively (Figure
3.3 and Table 1). We were able to see a more potent effect of the inhibitors DDD100097
and DDD100144 when tested directly against ICA. This suggests that by improving the
translocation of these two compounds into the mammalian host cell, the potency of the
inhibitors against the intracellular parasites would be enhanced. DDD85646 had shown
high efficacy against T. brucei, both in vitro and in vivo. Interestingly, in T. cruzi this
compound displayed an IC50 of 1.14 µM (Figure 3.2.C) in the proliferation assay and
showed no significant trypanocidal activity against purified ICAs (Figure 3.3). The drug
of reference, Benznidazole, at a concentration of 800 µM did not have a significant
effect on parasite viability. To determine the cytotoxic effects of these compounds on
mammalian cells, we performed a viability assay on U2OS cells. Using high content
imaging we were able to differentiate dead cells by the uptake of propidium iodide. After
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48 hours of treatment, compounds DDD86481, DDD100097, and DDD100144 showed
toxicity only at 50 µM, while there was no significant effect at lower concentrations
(Figure 3.4). Since almost complete inhibition of intracellular proliferation of the parasite
was observed at concentrations as low as 10 µM there is a window of selectivity
between human NMT and T. cruzi NMT (Table 1). Interestingly, the epimastigote form
of the parasite was less susceptible to these compounds. No significant difference was
observed on the viability of the parasite when increasing the length of the treatment
from 48 to 72 hours. After 72 hours, DDD86481 did not have a significant effect on
parasite viability, while DDD100097 and DDD100144 showed an IC50 of 9.68 µM and
2.14 µM, respectively (Figure 3.5).
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Figure 3.3. DDD compounds are trypanocidal against purified intracellular amastigotes.
Total number of parasites in each well was counted to evaluate the cytotoxicity of the
compounds against purified intracellular amastigotes.
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Figure 3.4. DDD compounds are only toxic at high concentrations against mammalian
cells.
Total number of cells in each well was counted to evaluate the cytotoxicity of the
compounds against U2OS cells.
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A

B

Figure 3.5. DDD compounds are less effective on the epimastigote form of the parasite.
Parasite viability was quantitatively measured after (A) 48 and (B) 72 hours of treatment
using a fluorometer at excitation 560nm, emission 590 nm.
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Inhibitors act “on target”

To determine whether these inhibitors are acting on TcNMT, we labeled epimastigotes,
amastigotes and trypomastigotes with myristic acid azide (Life Technologies), which
had been previously incubated with or without 10 µM of the inhibitors. Detection of Nmyristoylated proteins is typically performed by metabolic labeling with radioactive [3H]myristate. Alternatively, we used a bioorthogonal labeling method. In the first step, an
azido-myristic acid analog was actively incorporated into the parasites. In the second
step, the “click” reaction, the azide-modified proteins reacted with a chemoselective
alkyne-biotin. After SDS-PAGE and in-gel western blot analysis with IRDye® 800CW
Streptavidin (Licor), several putative N-myristoylated proteins were visualized. To
confirm that these proteins were indeed N-myristoylated duplicate gels were treated
with 0.2 M NaOH in methanol to remove any base-labile hydroxy- or thioester- linked
myristic acid azide. Treatment with base prior to scanning showed no difference in the
number of bands indicating that they are N-myristoylated proteins (data not shown).
Two bands, at 70 and 250 kDa, were present in all samples. They probably represent
proteins that are endogenously biotynilated; such as the biotin-dependent carboxylases,
3-methylcrotonyl-CoA and acetyl-CoA carboxylase which have been extensively
characterized in T. brucei (Vigueira and Paul 2011). Incubation of the parasites with 10
µM of DDD86481, DDD100097 and DDD100144 for 12 hours resulted in either a
decreased intensity or complete loss of most of the bands in all the stages of the
parasite (Figure 3.6). To determine whether these compounds specifically inhibited Nmyristoylation, parasites from the three different stages of T. cruzi were labeled with

49

[35S] methionine. Treatment with DDD86481, DDD100097 and DDD100144 had no
effect on the incorporation of [35S] methionine into proteins (Figure 3.7), indicating that
the inhibitors do not affect protein translation. This data suggests that the DDD
compounds specifically inhibit N-myristoylation in all T. cruzi stages and that this is
directly linked to inhibition of proliferation.
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A

B

C

Figure 3.6. DDD compounds specifically inhibit TcNMT.
In-gel western blots of lysates of (A) Epis, (B) ICAs and (C) TCTs treated with or without
10 µM of the inhibitors, labeled with myristic acid azide followed by “click” reaction with
biotin alkyne. IRDye® 800CW streptavidin was used to detect myristoylated proteins.
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A

B

C

Figure 3.7. DDD compounds do not affect protein translation.
Fluorographs of PVDF membranes from lysates of (A) Epis, (B) ICAs and (C) TCTs
treated with or without 10 µM of the inhibitors, labeled with [35S] methionine.

52

DDD compounds decrease the overall levels of myristic acid in epimastigotes

To determine if the overall cellular levels of myristic acid in treated parasites were
affected, we labeled Epis, ICAs and TCTs with myristic acid azide, followed by “click”
reaction with Alexa Fluor® 488 alkyne. Fluorescence microscopy showed a decrease in
the intensity of the signal in Epis (Figure 3.8) treated with the three compounds after 12
hours relative to the untreated parasites. In the case of ICAs (Figure 3.9) only
DDD100097 and DDD100144 affected the total levels of myristic acid. In TCTs there
was no observable reduction in the amount of myristic acid (Figure 3.10). In order to
determine the total levels of myristic acid quantitatively, we used in-cell western blot
analysis. In brief, we labeled treated parasites with myrisitic acid azide, followed by
“click” reaction with biotin alkyne. To detect the levels of myristic acid we used IRDye®
800CW Streptavidin. The streptavidin signal was normalized to the levels of BiP
(binding protein), by using rabbit anti-BiP (Bangs, Uyetake et al. 1993) followed by
detection with IRDye® 680RD anti-rabbit IgG. A significant reduction in the levels of
total levels of myristic acid was observed in treated Epis (Figure 3.11). However, we
were unable to see this effect in treated ICAs and TCTs.
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Figure 3.8. Overall levels of myristic acid in epimastigotes treated with DDD
compounds.
Fluorescence microscopy of Epis treated with 10 µM of the inhibitors and metabolically
labeled with myristic acid azide were reacted with Alexa® 488 alkyne (green) after
permeabilization, co-stained with DAPI (blue) to label the nucleus and kinetoplast. Scale
bar, 5 µm.
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Figure 3.9. Overall levels of myristic acid in amastigotes treated with DDD compounds.
Fluorescence microscopy of ICAs treated with 10 µM of the inhibitors and metabolically
labeled with myristic acid azide were reacted with Alexa® 488 alkyne (green) after
permeabilization, co-stained with DAPI (blue) to label the nucleus and kinetoplast. Scale
bar, 5 µm.
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Figure 3.10. Overall levels of myristic acid in trypomastigotes treated with DDD
compounds.
Fluorescence microscopy of TCTs treated with 10 µM of the inhibitors and metabolically
labeled with myristic acid azide were reacted with Alexa® 488 alkyne (green) after
permeabilization, co-stained with DAPI (blue) to label the nucleus and kinetoplast. Scale
bar, 5 µm.
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Figure 3.11. Quantitative analysis of overall levels of myristic acid in epimastigotes
treated with DDD compounds.
In-cell western blot of Epis treated with 10 µM of the inhibitors for 12 hours and
metabolically labeled with myristic acid azide, followed by “click reaction” with biotin
alkyne. Myristic acid levels were normalized to the levels of BiP.
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Epimastigotes treated with DDD compounds overexpress NMT

To investigate the expression and cellular localization of TcNMT in parasites
treated

with

the

compounds,

Epis,

ICAs

and

TCTs

were

analyzed

by

immunofluorescence after 12 h of treatment with 10 µM of DDD86481, DDD100097 and
DDD100144. Anti-TcNMT was obtained from rabbit sera rose against the TcNMT
peptide RGDGNLHYYFYNWSYP (Biomatik). Anti-TcNMT labeling in treated parasites
showed the same cellular localization as that seen in untreated parasites. Nonetheless,
Epis treated with the three different inhibitors showed an increased signal, suggesting
overexpression of this enzyme (Figure 3.12). In ICAs the same effect was observed with
all the inhibitors (Figure 3.13), while only TCTs treated with DDD86481 and
DDD100097 showed increased signal whereas DDD100144 did not affect TcNMT
expression (Figure 3.14). To confirm these results in a more quantitatively manner, we
used western blot analysis on lysates from parasites treated with or without the
inhibitors. TcNMT in lysates from wild type parasites could not be detected by western
blotting, probably due to low expression in all stages of T. cruzi. However, treated Epis
showed an overexpression of TcNMT that was detectable by western blotting (Figure
3.15). We were unable to see the same phenomenon in lysates from ICAs and TCTs
pre-incubated with the DDD compounds. These data suggest that the slight increment
in TcNMT signal observed in immunofluorescence analysis in treated ICAs and TCTs
might be not significant. Moreover, these observations may explain the increased
resistance of Epis to the inhibitors (Figure 3.5). Even though we still see a reduction in
protein N-myristoylation in Epis (Figure 3.6), the overexpression of TcNMT might be
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enough to compensate for the inhibitory effects of the compounds, rendering these
parasites less susceptible to the treatment. Encouragingly, these data further confirms
the “on-target” effect of these compounds.
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Figure 3.12. TcNMT expression in epimastigotes treated with DDD compounds.
Immunofluorescence microscopy of Epis treated with 10 µM of the inhibitors. Cells are
shown as viewed under phase contrast, visualized for fluorescence with anti-TcNMT
(red), co-stained with DAPI to reveal positions of the nucleus and kinetoplast (blue).
Scale bar, 5 µm.
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Figure 3.13 TcNMT expression in amastigotes treated with DDD compounds.
Immunofluorescence microscopy ICAs treated with 10 µM of the inhibitors. Cells are
shown as viewed under phase contrast, visualized for fluorescence with anti-TcNMT
(red), co-stained with DAPI to reveal positions of the nucleus and kinetoplast (blue).
Scale bar, 2 µm.
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Figure 3.14 TcNMT expression in trypomastigotes treated with DDD compounds.
Immunofluorescence microscopy TCTs treated with 10 µM of the inhibitors. Cells are
shown as viewed under phase contrast, visualized for fluorescence with anti-TcNMT
(red), co-stained with DAPI to reveal positions of the nucleus and kinetoplast (blue).
Scale bar, 2 µm.
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Figure 3.15. TcNMT is overexpressed in epimastigotes treated with DDD compounds.
Epis were treated with for 12 hours with or without 10 µM of the inhibitors. Levels of
NMT expression were confirmed by western blotting using anti-TcNMT. BiP (binding
protein) was used as a loading control.
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Chapter 4: Discussion and Final Conclusions

Despite the impressive advances in understanding the protozoan parasite T. cruzi,
Chagas disease continues to cause significant morbidity and mortality. Most of the
drugs available to threat this disease are decades old, limited in efficacy and present
severe side effects. Moreover, there are no vaccines available, which has classified
Chagas disease as a neglected tropical disease. There is an urgent need for new
chemotherapeutic targets and approaches aiming at the development of novel
compounds against this parasite. Here, we present the first evidence that validates T.
cruzi N-myristoyltransferase as a potential chemotherapeutic target.
N-myristoyltransferase has been intensively studied as a drug target for fungal and
parasitic infections. In T. cruzi over one hundred proteins have been predicted to be Nmyristoylated (Mills, Price et al. 2007), suggesting that TcNMT inhibition would have
pleotropic effects in the physiology of this parasite. For example, the flagellar calcium
binding protein (FCaBP), a protein involved in the transduction of a flagellum specific
calcium modulated signal, flagellar biosynthesis and movement, is both myristoylated
and palmitoylated. These acyl modifications are essential for flagellar association.
Alanine substitution at the glycine residue in the second position of the coding sequence
renders this protein cytosolic (Godsel and Engman 1999). Another protein, namely
phosphoinositide-specific phospholipase C (PI-PLC), has been experimentally validated
to be N-myristoylated. This modification is necessary for membrane targeting and for
stimulation of differentiation of the infective trypomastigote into the amastigote form
(Okura, Fang et al. 2005). Despite the obvious importance of this lipid modification in T.
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cruzi, no effort has been taken in exploring TcNMT as a potential drug target.
This work provides a promising starting point for the development of TcNMT as a
target for urgently needed antichagasic agents. The first part of this work focuses on the
expression and localization of TcNMT. Sequence analysis has shown conservation of
residues predicted to be essential for NMT activity. Interestingly, two ~30 aminoacid
insertions are found in TcNMT, suggesting additional secondary and tertiary structures
that could affect TcNMT activity relative to human NMT. These differences between
parasite and human NMT can be exploited in the development of specific TcNMT
inhibitors. NMTs from L. major and T. brucei have been shown to partition between
membrane and cytosolic fractions (Price, Menon et al. 2003; Panethymitaki, Bowyer et
al. 2006). Here we show by colocalization with BiP that TcNMT is at least partially
associated to the ER. Moreover, we provide evidence that NMT is constitutively
expressed, and most importantly present in those stages of T. cuzi that cause disease
in mammals, further highlighting the importance of this enzyme.
Furthermore, we have standardized the heterologous expression and purification
of recombinant TcNMT, which will allow for future kinetic analyses, and for the
development of in vitro inhibition assays. Recently, a “piggyback” approach, which
involves screening of antifungal NMT inhibitors, has been used in the development of
drugs against protozoan parasites (Bowyer, Tate et al. 2008). In L.major, T. brucei and
P. falciparum (Panethymitaki, Bowyer et al. 2006; Bowyer, Gunaratne et al. 2007), a
scintillation proximity assay using recombinant NMTs was used for high-throughput
screening of these antifungal NMT inhibitors. The same approach can be used in the
case of T. cruzi, where libraries of compounds can be screened against recombinant
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TcNMT.
Traditionally, detection of fatty-acylation has been performed by metabolic labeling
with radioactive fatty acids followed by visualization using autoradiography (Zeidman,
Jackson et al. 2009). Although effective, radioactivity often requires days to weeks to
visualize lipid-modified proteins. Recently, chemical reporters that enable rapid
detection of N-myristoylated proteins using bioorthogonal labeling methods (“click
chemistry”) have been developed (Charron, Zhang et al. 2009) and are now
commercially available (Life Technologies). Despite the availability of these reporters,
[3H] myristic acid continues to be the choice in the study of N-myristoylransferase in
protozoan parasites. Here, we have validated and standardized the metabolic labeling
of trypanosomes with azido-myristic acid analogs, followed by chemoselective ligation
with the corresponding hapten- or fluorophore-alkyne. This work presents, to our
knowledge, the first alternative, non-radioactive method to study N-myristoylation in
kinetoplastids.
The second part of this work focuses on the evaluation of NMT inhibitors as anti-T.
cruzi agents. Screening of a 62,000 diversity-based compound library against T. brucei
NMT, led to the discovery of potent inhibitors that cured trypanosomiasis in vivo
(Frearson, Brand et al. 2010). In this study we tested eight of this inhibitors against the
intracellular parasite T. cruzi. We have presented evidence of strong inhibition of
intracellular

amastigote

proliferation

particularly

with

compounds

DDD86481,

DDD100097 and DDD100144. Importantly, they did not show cytotoxic effects against
mammalian cells at effective trypanocidal concentrations. Interestingly, DDD85646,
which showed potent in vitro and in vivo activity against T. brucei, showed no
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trypanocidal activity against purified ICAs. In addition, we have demonstrated the “on
target” effect of these compounds by metabolic labeling with myristic acid azide. In-gel
western blots of lysates from parasites showed a significant decrease in protein Nmyristoylation relative to the untreated controls. Strikingly, Epis were less susceptible to
these compounds, which might be explained by the TcNMT overexpression observed in
this stage of the parasite. This overexpression suggests a compensation mechanism for
the inhibition of TcNMT, confirming the specificity of the inhibitors. Overall, it is likely
that the effects of the tested compounds are a result of several downstream events, as
this enzyme has over 100 putative substrates (Mills, Price et al. 2007). The lead
compounds hold great potential to be explored as antichagasic agents. Therefore,
additional studies will be carried out to further evaluate the in vivo effects of DDD86481,
DDD100097 and DDD100144 in the murine model of Chagas disease.
In conclusion, the results from this dissertation provide an insight in a novel
potential chemotherapeutic target in this parasite. Further characterization of this
enzyme will be aid by the techniques standardized in this work. Here, we have validated
TcNMT as a potential drug target in Chagas disease. Importantly, the tested
compounds demonstrated significant and specific anti-proliferative activity and hold
great potential to be explored as anti-T. cruzi agents. The knowledge accumulated
through these studies may eventually result in the development of improved
chemotherapeutics against Chagas disease.
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Appendix

List of abbreviations

BiP

Binding protein

BSA

Bovine serum albumin

BZ

Benznidazol

DAPI

4’6-diamidino-2-phenylindole

DMEM

Dulbeco’s modified eagle medium

DMSO

Dmethyl sulfoxide

DNA

Deoxyribonucleic acid

ER

Endoplasmic reticulum

Epi

Epimastigote

FPLC

Fast protein liquid chromatography

HI-FBS

Heat-inactivated fetal bovine serum

IC50

Half maximal inhibitory concentration

ICA

Intracellular amastigotes

IFA

Immunofluorescence assay

IPTG

Isopropyl β-D-thiogalactoside

LIT

Liver infusion tryptose

LLC-MK2

Rhesus monkey kidney epithelial cells

LmNMT

Leishmania major N-myristoyltransferase

NMT

N-miristoyltranferase

PBS

Phosphate buffered saline

PCR

Polymerase chain reaction

PFA

Paraformaldehyde

PI

Propidium iodide
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PVDF

Polyvinylidene fluoride

SDS

Sodium dodecyl sulfate

SDS-PAGE

Sodium dodecyl sulfate polyacrilamide gel electrphoresis

TbNMT

Trypanosoma brucei N-myristoyltranferase

TcNMT

Trypanosoma cruzi N-myrsitoyltransferase

TCT

Tissue culture cell-derived trypomastigotes

U2OS

Human osteocytes
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